Proteomes are an entire set of proteins which is expressed in genomes, and proteomics refers to the large-scale study of these proteomes, that include study of the functions and structure of proteins that can be used in diagnosis and treatment of various diseases, and in the process of drug discovery. Proteomics is used to analyze the interaction of proteins with each other, action of proteins in metabolic pathways, rate of the production of proteins, and the modification process of the proteins. Additionally, it is extensively applied in personalized medicine development, and marker identification for disease diagnosis. Global proteomics market is expected to grow significantly in the forecasted period due to the rising demand for personalized medicine and increasing investment in research and development activities, globally.
Based on the instrumentation technology, the global proteomics market is segmented into protein microarrays, spectroscopy, x-ray crystallography, chromatography, electrophoresis, surface plasmon resonance (SPR) systems, and protein fractionation systems. Protein microarray held the largest segment of the global market in 2016, mainly due to its ability to produce large number of results from a small sample. Moreover, it provides label-free detection, full imprint of proteins, and direct and absolute quantification.
On the basis of reagents, the global proteomics market is segmented into microarray reagents, protein fractionation reagents, spectroscopy reagents, x-ray crystallography reagents, chromatography reagents, electrophoresis reagents, and immunoassay reagents. Protein fractionation reagents are expected to have a significant growth during the period 2017 - 2023, mainly due to its increased application in simplifying complex proteins and making the research processes easier.
Based on software and services, analytical laboratory services held largest share of the global proteomics market in 2016, mainly due to increasing research and development investments by the key players in the market and government. The global proteomics market finds application in drug discovery, clinical diagnosis, and other applications. Based on application, clinical diagnostics held the largest share of the global proteomics market in 2016, driven by increasing understanding of proteins and its application in the drug discovery.
Global Proteomics market is expected to grow significantly during the forecast period. Some of the major factors driving growth of the global proteomics market are rising demand for personalized medicine, increasing research and development investments, technological advancements, and availability of government and private funding. Personalized medicine is manufactured according to the treatment condition and helps in the better treatment and quick recovery of the patients. The benefits of the personalized medicine for the treatment of different types of cancer is further driving the growth of the global proteomics market. Moreover, the technological advancements in the field of proteomics are prompting the key market players to invest in the proteomics market. These technological advancements also lead to the more government as well as private funding which is likely to positively impact the growth of the global proteomics market. In 2015, grants were offered by National Cancer Institute for Clinical Proteomic Tumor Analysis Consortium (CPTAC) program that aimed to accelerate the understanding of the molecular basis of cancer.
The expensive tools and instruments, and dearth of skilled researchers act as major barriers for the growth of the global proteomics market. For the study of the proteomics, the mass spectrometer approximately costs $20,000. Similarly, the cost of ion exchange chromatography and fraction collection is around $250 per sample. Such high cost restricts the growth of the proteomics market. Moreover, the proteomics study and research requires the involvement of skilled researchers as it includes critical and time-consuming researches. Since, proteomics is novel and developing approach to study proteins, therefor there is an extreme need of skilled researchers for the study of proteomics.
Opportunities and Trends
A key trend witnessed in the global proteomics market is the shift from genomics to proteomics, that has taken place due to its vast application in drug discovery and for treatment in various diseases. Also, the growing applications of biomarker identification is creating ample opportunities for the growth of the global proteomics market. Biomarker identification helps in providing better results in the proteomics researches and are used in the researches for finding the desirable outcomes. It is an opportunity for the players in the global proteomics markets as it enhances the quality of the research and provide better results. Thus, biomarkers are an attractive opportunity for the growth of the global proteomics market.
Insights by Geography
Geographically, North America was the largest market for Proteomics in 2016, followed by Europe. The North American proteomics market is primarily driven by easily available funds from various institutions for proteomic research using innovative technologies.
Due to the increased spending on healthcare in the developed market, various government and private institutions are funding on different projects which will drive the growth of the global proteomics market, Asia-Pacific is expected to witness the fastest in the period, 2017-2023, the improving infrastructure for research, and emerging markets is driving the growth of the region’s proteomics market. Government and private players are increasingly investing in the Asia-Pacific, since the region constitutes many untapped countries having potential customers.
Some of the key players in the global proteomics market are Agilent Technologies Inc., Bruker Corporation, GE Healthcare, Merck KGaA, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Waters Corporation, Danaher Corporation, Luminex Corporation, and PerkinElmer Inc.
With respect to strategic developments, various new product launches and strategic alliances have been taking place in the patient positioning equipment market.
In June 2017, Waters Corporation introduced the latest version of Progenesis QI for proteomics software. This software will enable the researchers to generate more results in comparatively less time.
In June 2017, Thermo Fisher Scientific Inc launched a new high-performing Orbitrap mass spectrometer. It is designed to produce superior quality results in the proteomics researches.